Clinical trial
GLEAM: Noninvasive Glucose Measurement Using Impedance Tomography - a Pilot Project
NCT06223204 is registered in ClinicalTrials.gov with Insel Gruppe AG, University Hospital Bern as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- GLEAM: Noninvasive Glucose Measurement Using Impedance Tomography - a Pilot Project
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- January 31, 2024
- Completion date
- April 10, 2024
- Enrollment
- 16 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.